Market revenue in 2023 | USD 126.5 million |
Market revenue in 2030 | USD 193.1 million |
Growth rate | 6.2% (CAGR from 2023 to 2030) |
Largest segment | Acute itp |
Fastest growing segment | Acute ITP |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Acute ITP |
Key market players worldwide | Amgen Inc, Roche, Grifols SA Ordinary Shares - Class A, GSK PLC, Intromedic, Medtronic PLC, FUJIFILM Holdings Corp, Olympus Corp |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to idiopathic thrombocytopenic purpura therapeutics market will help companies and investors design strategic landscapes.
Acute itp was the largest segment with a revenue share of 100% in 2023. Horizon Databook has segmented the Asia Pacific idiopathic thrombocytopenic purpura therapeutics market based on acute itp covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific idiopathic thrombocytopenic purpura therapeutics market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific idiopathic thrombocytopenic purpura therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account